From: CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer
Genes responsible for drug resistance | Type of cancer cell | Possible effects | References |
---|---|---|---|
SLFN11 | Lung cancer | Enhancing S-phase arrest Enhancing apoptosis Attenuating resistance to talazoparib | |
APE1 | Triple-negative breast cancer | Attenuating resistance to olaparib | [156] |
RSF1 | Lung cancer | Enhancing NFKB signaling Enhancing paclitaxel resistance | [158] |
CDK5 | Hepatocellular carcinoma | Enhancing sorafenib resistance | [161] |
ARID1A | Endometrial cancer | Upregulating PRB Enhancing cancer cell sensitivity to MPA | [163] |
Aurora-B | Lung cancer | Attenuating the p53-dependent DNA damage response Enhancing resistance to cisplatin and paclitaxel | [164] |
ATRX | Glioma | Enhancing ATM-dependent DNA repair Enhancing resistance to TMZ | [167] |
BIRC5 | Ovarian cancer | Enhancing EMT Enhancing paclitaxel resistance | [169] |
PBRM1 | Lung cancer | Attenuating AKT signaling Enhancing effectiveness of EGFR inhibitors | [174] |
SGOL1 | Hepatocellular carcinoma | Enhancing cytotoxic effect of sorafenib | [177] |
Tceal1 | Prostate cancer | Increasing cell death, polyploidy, and docetaxel sensitivity might happen after knockout | [178] |
ABCC9 and IL37 | Cervical cancer | Paclitaxel resistance | [179] |
MSH2 | Bladder cancer | Reducing apoptotic effect of cisplatin might happen after gene knockout | [180] |
ELP5 | Gallbladder cancer | Poor survival might happen after ELP5 knockout and gemcitabine treatment | [181] |
Farnesyltransferase | Renal cell carcinoma | Sunitinib resistance | [182] |
FBXO42 | NRAS-mutant melanoma | Trametinib resistance | [183] |
LZTR1, NF1, and TSC1 or TSC2 | Acute myeloid leukemia | Sorafenib resistance | [184] |
BEND3 | Acute myeloid leukemia | Increasing ABCG2 level, reducing TAK-243 in the cell and drug resistance | [185] |
Wnt/B-catenin | k-ras mutated colorectal cancer | ABT-263 resistance | [186] |
MSH2, CLCA2, and PTCH2 | Glioblastoma | TMZ resistance | [187] |